Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fresenius Medical Care publishes 2021 Global Annual Medical Report: Embracing the Complexity of Global Healthcare

09/23/2021 | 09:32am EDT

Press Release

September 23, 2021

Media Contact

Michael Gavin

  1. +49 6172 609-2978 michael.gavin@fresenius.com

Media Contact for North America Brad Puffer

  1. +1 781-699-3331brad.puffer@fmc-na.com

Contact for analysts and investors

Dr. Dominik Heger

  1. +49 6172 609-2601dominik.heger@fmc-ag.com

www.freseniusmedicalcare.com

Fresenius Medical Care publishes 2021 Global Annual Medical Report: Embracing the Complexity of Global Healthcare

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, announced publication of its 2021 Global Annual Medical Report. Titled "Embracing the Complexity of Global Healthcare," the report focuses on addressing healthcare complexities by driving meaningful advances in kidney disease care.

"The volume of thought leadership, ideas and expertise in the report demonstrates our company's continued leadership in kidney care, our innovation through lifelong learning and our commitment to our patient-centered mission," said Franklin W. Maddux, MD, Global Chief Medical Officer of Fresenius Medical Care.

The 2021 Global Annual Medical Report comprises 25 chapters by more than 40 authors from across the company. Six different sections each focus on a core theme of Fresenius Medical Care's Clinical & Quality Agenda. An additional COVID-19 section is dedicated to the company's ongoing efforts to address the pandemic.

The core themes are:

  • Cardiovascular Health
  • Precision Medicine
  • Communication and Medical Education
  • Global Research

Page 1/2

  • Patient-CenteredCare
  • Innovation and Transformation

The 2021 Global Annual Medical Report is published by the Global Medical Office of Fresenius Medical Care. The full report is now available online at: https://www.freseniusmedicalcare.com/en/about-us/sustainability/medical-responsibility/

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.7 million patients worldwide regularly undergo dialysis treatment. Through its network of more than 4,100 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 346,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the company focuses on expanding in complementary areas and in the field of critical care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company's website at www.freseniusmedicalcare.com.

Disclaimer:

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Page 2/2

Disclaimer

FMC - Fresenius Medical Care AG & Co. KGaA published this content on 23 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 September 2021 13:31:04 UTC.


ę Publicnow 2021
All news about FRESENIUS MEDICAL CARE AG & CO. KGAA
10/26European ADRs Move Higher in Tuesday Trading
MT
10/26FMC FRESENIUS MEDICAL CARE AG & CO K : Deutsche Bank reiterates its Neutral rating
MD
10/26FMC FRESENIUS MEDICAL CARE AG & CO K : Berenberg remains its Buy rating
MD
10/25FRESENIUS MEDICAL CARE : further enhances clinical care through continuous digital quality..
PU
10/22FMC FRESENIUS MEDICAL CARE AG & CO K : JP Morgan maintains a Sell rating
MD
10/21FMC FRESENIUS MEDICAL CARE AG & CO K : Barclays reaffirms its Neutral rating
MD
10/18European ADRs Move Lower in Monday Trading
MT
10/07FMC FRESENIUS MEDICAL CARE AG & CO K : Jefferies maintains a Sell rating
MD
10/07FMC FRESENIUS MEDICAL CARE AG & CO K : NorldLB reiterates its Buy rating
MD
10/07Fresenius Medical Care AG & Co. KGaA acquired Sugerencias Medicas S.A.
CI
More news
Analyst Recommendations on FRESENIUS MEDICAL CARE AG & CO. KGAA
More recommendations
Financials (USD)
Sales 2021 21 038 M - -
Net income 2021 1 259 M - -
Net Debt 2021 13 413 M - -
P/E ratio 2021 15,8x
Yield 2021 2,03%
Capitalization 20 097 M 20 096 M -
EV / Sales 2021 1,59x
EV / Sales 2022 1,49x
Nbr of Employees 123 538
Free-Float 67,8%
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Last Close Price 68,60 $
Average target price 80,24 $
Spread / Average Target 17,0%
EPS Revisions
Managers and Directors
Rice Powell Chief Executive Officer
Helen Giza Chief Financial Officer
Dieter Schenk Chairman-Supervisory Board
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer
Sector and Competitors